Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 53.4% | -2.8% | -19.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 89.6% | 93.9% | 98.5% | 99.3% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 15.9% | -14.5% | -44.8% | -7.6% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 9.8% | -21.5% | -48.7% | -12% |
| EPS Diluted | 0.99 | -1.44 | -3.4 | -1.1 |
| % Growth | 168.7% | 57.6% | -209.1% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |